Biolegend, 100726, Alexa Fluor® 488 anti-mouse CD8a Antibody
25microg
Catalog Number: 100726
| Verified Reactivity | Mouse |
|---|---|
| Antibody Type | Monoclonal |
| Host Species | Rat |
| Immunogen | Mouse thymus or spleen |
| Formulation | Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide. |
| Preparation | The antibody was purified by affinity chromatography and conjugated with Alexa Fluor® 488 under optimal conditions. |
| Concentration | 0.5 mg/ml |
| Storage & Handling | The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze. |
| Application | FC - Quality tested 3D IHC - Verified |
| Recommended Usage | Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. For 3D immunohistochemistry on formalin-fixed tissues, a concentration of 5.0 µg/mL is suggested. It is recommended that the reagent be titrated for optimal performance for each application. * Alexa Fluor® 488 has a maximum emission of 519 nm when it is excited at 488 nm. Alexa Fluor® and Pacific Blue™ are trademarks of Life Technologies Corporation.View full statement regarding label licenses |
Unless otherwise stated, the minimum order amount is USD 1,000.
For orders below USD 1,000, an additional handling fee may apply, or we may arrange local delivery / local handover where available.
All quotations are subject to final confirmation, including product availability, lead time, batch information, shipping cost, and applicable export or handling requirements.
For quotation requests, please send an RFQ from website or contact:
Please send inquiries directly to us in the “To” field. Emails sent via BCC, mass mailing, or with unrelated recipients may be automatically filtered and will not be processed.
| Excitation Laser | Blue Laser (488 nm) |
|---|
| Application Notes | Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746). |
|---|
| Application References(PubMed link indicates BioLegend citation) | Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP) Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete) Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP) Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block) Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC) Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC) Shih FF, et al. 2006. J. Immunol. 176:3438. (FC) Kamimura D, et al. 2006. J. Immunol. 177:306. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete) Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed Lee CH, et al. 2009. Clin. Cancer Res. PubMed Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed Guo Y, et al. 2008. Blood 112:480. PubMed Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed Kenna TJ, et al. 2008. Blood 111:2091. PubMed Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed Medyouf H, et al. 2010. Blood 115:1175. PubMed Riedl P, et al. 2009. J. Immunol. 183:370. PubMed Apte SH, et al. 2010. J. Immunol. 185:998. PubMed Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed Cui L, et al. 2015. J Control Release. 206:220. PubMed Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed |
|---|
| Product Citations | Moderzynski K, et al. 2016. PLoS Negl Trop Dis. . PubMed Hirai T, et al. 2020. Immunity. 54(1):84-98.e5. PubMed Cignarella F et al. 2018. Cell metabolism. 27(6):1222-1235 . PubMed Diamantopoulou Z, et al. 2022. Nature. 607:156. PubMed Balakrishnan PB, et al. 2022. Nano Res. 15:2300. PubMed Barsheshet Y, et al. 2022. Int J Mol Sci. 23:. PubMed Pani F, et al. 2021. Endocrinology. 162:. PubMed Shenoy AT, et al. 2022. Cytometry A. 101:892. PubMed Zhang Z, et al. 2022. Mol Nutr Food Res. 66:e2200300. PubMed Pinto NA, et al. 2023. Cell Death Differ. :. PubMed Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed Reticker-Flynn NE, et al. 2022. Cell. 185:1924. PubMed Suzuki K, et al. 2019. Cell Mol Gastroenterol Hepatol. 8:119. PubMed Yang Z, et al. 2022. J Immunother Cancer. 10:. PubMed Ooi JD, et al. 2019. Nat Commun. 10:3392. PubMed Baptista AP et al. 2019. Immunity. 50(5):1188-1201 . PubMed Periasamy S, et al. 2017. Nat Commun. 8:15564. PubMed Gu H, et al. 2021. Immun Inflamm Dis. 9:1686. PubMed Onishi S, et al. 2015. PLoS One. 10:126564. PubMed Tang B, et al. 2020. Clin Cancer Res. 26:2216. PubMed Nagai Y, et al. 2019. Front Immunol. 10:174. PubMed Joseph R, et al. 2021. Br J Cancer. 125:176. PubMed Paprckova D, et al. 2022. Front Immunol. 13:1009198. PubMed Zhuang Z, et al. 2021. J Exp Med. 218:00:00. PubMed Yang H, et al. 2015. Cancer Res . 75: 3812-3822. PubMed Mastandrea I, et al. 2022. STAR Protoc. 3:101106. PubMed Bartkowiak T, et al. 2015. Proc Natl Acad Sci U S A. 112: 5290-5299. PubMed Zhang Y, et al. 2015. PLoS Pathog. 11: e1005167. PubMed Xiao Y, et al. 2021. Cancer Cell. 39(3):423-437.e7. PubMed Lin JR et al. 2018. eLife. 7 pii: e31657. PubMed Uchil PD et al. 2018. Cell host & microbe. 25(1):87-100 . PubMed Chen C, et al. 2019. Cell Rep. 29:4200. PubMed An J, et al. 2022. iScience. 25:103570. PubMed Cassidy BR, et al. 2020. J Neuroinflammation. 17:259. PubMed Yamada T, et al. 2016. J Immunol. 197: 4079 - 4089. PubMed Glassman CR, et al. 2021. eLife. 10:00. PubMed Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed Xiong H, et al. 2021. Theranostics. 11:1594. PubMed Reinfeld BI, et al. 2021. Nature. 593:282. PubMed Kim S, et al. 2021. Elife. 10:. PubMed Ma S, et al. 2022. Cell Rep. 38:110520. PubMed Stirling ER, et al. 2022. J Immunother Cancer. 10:. PubMed Covarrubias AJ, et al. 2020. Nat Metab. 1265:2. PubMed Collins N, et al. 2016. Nat Commun. 7:11514. PubMed Simula L et al. 2018. Cell reports. 25(11):3059-3073 . PubMed Mantilla-Rojas C, et al. 2022. Cancers (Basel). 14:. PubMed Sun J, et al. 2020. Cell. 182:734. PubMed Lee C, et al. 2009. Clin Cancer Res. 2.538888889. PubMed Long C, et al. 2016. Toxicol Sci. 152: 85 - 98. PubMed Isvoranu G, et al. 2019. Oncol Lett. 17:4197. PubMed Chen ST et al. 2019. Cell host & microbe. 25(4):602-616 . PubMed Kaddatz H, et al. 2020. Glia. 69:925. PubMed Dholakia J, et al. 2022. Gynecol Oncol. 164:170. PubMed Asadi Shahmirzadi A, et al. 2020. Cell Metabolism. 32(3):447-456.e6. PubMed Huo M, et al. 2017. FASEB J. 10.1096/fj.201601030R. PubMed Klose R, et al. 2016. Nat Commun. 7:12528. PubMed Zhu J et al. 2017. Cell stem cell. 20(3):374-384 . PubMed Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed Nakamura K, et al. 2018. Cancer Cell. 33:634. PubMed Rudd CE, et al. 2020. Cell Reports. 30(7):2075-2082. PubMed Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed Simula L, et al. 2022. Mol Oncol. 16:188. PubMed Simula L, et al. 2020. Cell Death Differ. 27:2749. PubMed Conforti A, et al. 2021. Mol Ther. S1525-0016:00466. PubMed |
|---|
| RRID | AB_493423 (BioLegend Cat. No. 100726) AB_389304 (BioLegend Cat. No. 100723) |
|---|
| Structure | Ig superfamily, CD8α chain, 34 kD |
|---|
| Distribution | Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells |
|---|
| Function | Co-receptor for TCR |
|---|
| Ligand/Receptor | MHC class I molecule |
|---|
| Antigen References | 1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Zamoyska R. 1994. Immunity 1:243. 3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523. |
|---|
| Gene ID | 12525 |
|---|
| UniProt | View information about CD8alpha on UniProt.org |
|---|
| Clone | 53-6.7 |
|---|
| Regulatory Status | RUO |
|---|
| Other Names | T8, Lyt2, Ly-2 |
|---|
| Isotype | Rat IgG2a, κ |
|---|